2017 Annual conference in multiple sclerosis High-quality care for improved patient outcomes

Neurology

Multiple sclerosis

International conference by Excemed

Friday, Mar 3 2017

Rome, Italy

Language

English

Registration status

Closed

Target audiences

Neurologists involved in MS management.

Files

Final Programme

Introduction

Access resources by clicking the Outcomes tab or scroll down to the Scientific Programme.

This live scientific programme is endorsed by the European Academy of Neurology (EAN)

Call for abstracts

EXCEMED – Excellence in Medical Education - and the Chairs of the upcoming 2017 Annual conference in multiple sclerosis (3 March 2017, Rome, Italy) invite abstract submissions on the occasion of this international conference.

Prospective presenters are invited to send an abstract on hot topics in multiple sclerosis meeting the following criteria:

Abstracts must be 300 words, written in English and contain:

a clearly stated main objective
a description of the topic or issue covered in the presentation
an emphasis on the critical issues relating to specific topics in the presentation
a summary containing conclusions

The conference scientific committee will review abstracts and select the successful applications.

EXCEMED will provide free conference registration, travel, transfer and accommodation to presenters whose abstract has been selected.

Abstract submission deadline: 17 February 2017

Send your abstract to: alessia.addessi@excemed.org

Overview

Novel immunological insights into multiple sclerosis (MS) pathogenesis have revolutionized the traditional therapeutic approach. Numerous therapeutic options are available for individuals with MS, but the wide choice may present challenges for clinicians. Selecting the most appropriate treatment – one that targets specific disease manifestations and fulfils patient requirements − has created the need for individual biomarkers to be developed. There is also increasing demand for detailed information about MS to be widely available, particularly with regard to the risk/benefit profiles of specific treatments. Such information needs to be provided directly to patients, who are active players in the ‘therapeutic contract’. The aim of this programme is to update each of these emerging issues in MS, offer practical suggestions for disease management and enhance communication with patients in daily practice.

Learning objectives

Illustrate the main immunological abnormalities apparent in relapsing remitting and progressive MS forms
Define the most important de-risking strategies in MS treatments to be applied in clinical practice
Explain treatment algorithms for highly active MS, extending beyond first-line approaches
Outline the importance of patient-reported outcomes in clinical practice and clinical trials

Accreditation details

EXCEMED (www.excemed.org) is accredited by the European Accreditation
Council for Continuing Medical Education (EACCME ® ) to provide the following
CME activity for medical specialists. The EACCME ® is an institution of the
European Union of Medical Specialists (UEMS), www.uems.net
The CME conference “High-quality care for improved patient outcomes"
to be held on 3 March 2017 in Rome, Italy is designated for a maximum of 6 (six) hours of European CME
credits (ECMEC). Each medical specialist should claim only those credits that
he/she actually spent in the educational activity. EACCME ® credits are recognized
by the American Medical Association (AMA) towards the Physician's Recognition
Award (PRA). To convert EACCME ® credit to AMA PRA category 1 credit, please
contact the AMA.

The CME conference has been designated for 2,1 Italian CME Credits. N. Event 178465 Ed.
1 - Provider Id n. 3255 from the Italian Ministry of Health.

Scientific programme

8.15 Welcome and opening

SESSION I: Understanding MS

8.30 L1 Immunological signatures in relapsing remitting and progressive MS

D. Centonze (Italy)

8.50 L2 The compartmentalized immune response in MS

A. Bar-Or (Canada)

9.10 L3 Neuroinflammation: role of genes and environment

J. Hillert (Sweden)

9.30 Q&A

10.00 Coffee break

SESSION II: Treating MS

10.30 L4 Biomarkers in CNS Demyelinating Diseases

A. Bar-Or (Canada)

10.50 L5 Risks associated with MS treatment

L. Klotz (Germany)

11.10 L6 De-risking strategies in clinical practice

P. Rieckmann (Germany)

11.30 L7 DMDs: long-term studies

G. Comi (Italy)

11.50 PD1 Panel discussion: treatment goals

Moderator: C. Pozzilli (Italy)

12.30 Lunch

SESSION III: Managing MS − Workshops

This session includes two different parallel workshops, each lasting 1 hour. Participants will be divided into groups and will attend both workshops in rotation. By the end of the session each participant will have attended both workshops.

Workshop I − Predicting treatment response in each patient: switching algorithms in the new landscape

X. Montalban (Spain) and L. Klotz (Germany) Slide kit

Workshop II – How to manage highly active MS patients in practice

G. Comi (Italy) Slide kit and G. Giovannoni (UK) Slide kit

15.30 Coffee break

SESSION IV: Patient−doctor communications about MS

16.00 L8 The therapeutic contract – the doctor’s perspective

G. Giovannoni (UK)

16.20 L9 The therapeutic contract- the patient’s perspective

R. de Boer (The Netherlands)

16.40 L10 Patient-centered outcomes and clinical trials

A. Solari (Italy)

17.00 Q&A

17.20 Panel discussion: unmet needs in MS

Moderator: D. Bates (UK)

17.50 Scientific highlights and meeting wrap-up

18.00 End of the conference

CME provider

EXCEMED - Excellence in Medical Education

Chair(s)

Giancarlo Comi

Department of Neurology

Institute of Experimental Neurology

Vita-Salute San Raffaele University

Milan, Italy

David Bates

Department of Neurology

Royal Victoria Infirmary

Newcastle upon Tyne, United Kingdom

Speakers

Amit Bar-Or

Neurologist and Professor

Department of Neurology and Neurosurgery

Clinical Research Unit

Montreal Neurological Institute

Montreal, Canada

David Bates

Department of Neurology

Royal Victoria Infirmary

Newcastle upon Tyne, United Kingdom

Diego Centonze

Neurology Unit

IRCSS Mediterraneo Neuromed Neurology Institute

Rome, Italy

Giancarlo Comi

Department of Neurology

Institute of Experimental Neurology

Vita-Salute San Raffaele University

Milan, Italy

Gavin Giovannoni

Chair of Neurology

Department of Neurology

Institute of Cell and Molecular Science

Queen Mary University London & Barts and The London NHS Trust

London, United Kingdom

Hans Peter Hartung

Director of the Center for Neuropsychiatry and Chair of the Department of Neurology

Department of Neurology

Heinrich-Heine-University Duesseldorf

Dusseldorf, Germany

Jan Hillert

Department of Clinical Neuroscience

Karolinska Institute

Stockholm, Sweden

Xavier Montalban

Vall d’Hebron University Hospital

Neurology-Neuroimmunology Department

Multiple Sclerosis Centre of Catalonia (Cemcat)

Barcelona, Spain

St. Michael’s Hospital

Division of Neurology

University of Toronto

Toronto, Canada

Carlo Pozzilli

Department of Neurology and Psychiatry

La Sapienza University of Rome

Rome, Italy

Peter Rieckmann

Bamberg Hospital and University of Erlange

Bamberg, Germany

Alessandra Solari

Unit of Neuroepidemiology

Foundation IRCCS Neurological Institute C. Besta

Milano, Italy

Heinz Wiendl

Direktor | Univ.-Prof. Prof. h.c. Dr. med.

Department für Neurologie

Klinik für Allgemeine Neurologie | University of Münster Münster | Institut für Translationale Neurologie

Albert-Schweitzer-Campus 1, Gebäude A1

Münster, 48149, Germany

Registration/Accommodation

For registration, accommodation and any logistic inquiry please contact:
Meridiano Congress International (Italy)
Senior Event Manger: Titty Alvino
T +39 06 88 595 310 - F +39 06 88595 234
titty.alvino@meridiano.it